Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

SOHO 2020 | APR-246 in TP53 mutated MDS and AML

David Sallman • 3 Sep 2020
SOHO 2020
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Azacitidine Eprenetapopt Venetoclax

David Sallman, MD, H. Lee Moffitt Cancer Center, Tampa, FL, updates us on the use of APR-246, a p53 targeted therapy, evaluated with azacitidine in TP53 mutated MDS and acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from David Sallman

Novel targets for T-cell engagers in relapsed/refractory AML
10:17
Novel targets for T-cell engagers in relapsed/refractory AML
David Sallman • 19 Sep 2026
Phase IIa trial of ofirnoflast, a first-in-class allosteric NEK7 inhibitor, in ESA-refractory LR-MDS
7:19
Phase IIa trial of ofirnoflast, a first-in-class allosteric NEK7 inhibitor, in ESA-refractory LR-MDS
David Sallman • 1 Oct 2026
Lessons from Phase I KITE-222: antigen escape, expansion, and the future of CAR-T in AML
4:14
Lessons from Phase I KITE-222: antigen escape, expansion, and the future of CAR-T in AML
David Sallman • 1 Oct 2026
Lessons from Phase III ENHANCE: TP53, transplant, and MRD in future HR-MDS combination trials
4:28
Lessons from Phase III ENHANCE: TP53, transplant, and MRD in future HR-MDS combination trials
David Sallman • 1 Oct 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals